Status:

RECRUITING

Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With EVT on Long-term Prognosis in Patients With AIS (PPDET)

Lead Sponsor:

Beijing Chao Yang Hospital

Conditions:

Acute Ischemic Stroke

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

Dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. The investigators hypothesized that the prolonged sedation o...

Detailed Description

Endovascular treatment with mechanical thrombectomy is the standard treatment for acute large vessel occlusion. Dexmedetomidine is a commonly used sedative in endovascular thrombectomy of acute ische...

Eligibility Criteria

Inclusion

  • 2≤NIHSS≤25
  • mRS score before stroke was less than 3
  • Acute ischemic stroke (including anterior circulation)
  • mTICI rate 2b or 3
  • According to the 2018 AHA/ASA guidelines for the management of acute ischemic stroke, patients who plan to receive mechanical thrombectomy under local anesthesia and sedation
  • Informed consent was signed by patient or legal representative

Exclusion

  • Intracerebral hemorrhage occurred in the responsible vessel area in the past 6 weeks
  • Patients who had received stent treatment at the responsible vessel in the past
  • Neurological function was restored at or before angiography
  • Patients who are allergic to heparin, aspirin, clopidogrel, rapamycin, lactic acid polymer, poly (n-butyl methacrylate), stainless steel, anesthetics and contrast agents or have contraindications
  • Hemoglobin was less than 70g/L, platelet count was less than 50×109/L, international normalized ratio (INR) greater than 1.5 (irreversible), there are uncorrectable bleeding factors
  • Blood glucose \< 2.7 mmol/L or \> 22.2 mmol/L
  • Severe liver or kidney disfunction, ALT\>3 times the upper limit of normal value or AST\>3 times the upper limit of normal value, creatinine\>1.5 times the upper limit of normal value
  • Pregnant or lactating women
  • Previous history of mental illness
  • Stroke with other acute diseases or postoperative stroke of other operation
  • Heart rate less than 50bpm, second or third degree of atrioventricular block (except for pacemaker implantation), systolic blood pressure less than 90mmHg (two vasoactive drugs were already infused continuously )

Key Trial Info

Start Date :

March 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

368 Patients enrolled

Trial Details

Trial ID

NCT04916197

Start Date

March 1 2024

End Date

December 1 2026

Last Update

December 20 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beijing ChaoYang Hospital

Beijing, Beijing Municipality, China, 100020